致癌KRAS驱动肺癌中肿瘤抑制的功能分类
研究利用多重组小鼠模型,在体内系统量化48个已知和推定肿瘤抑制基因对致癌KRAS驱动肺癌起始、生长和进展的影响,揭示此前研究不足的功能性肿瘤抑制因子,并发现肿瘤抑制格局的复杂性,对理解癌症演化及临床基因组测序解读有启示。
要点
- 多重组小鼠模型可高通量解析肿瘤抑制基因在体内的功能。
- 部分基因失活显著促进肿瘤生长,另一些促进起始或异常大肿瘤出现。
- 肿瘤抑制功能分类反映癌症生命周期中约束条件的动态变化。
核心结论
- 致癌KRAS驱动肺癌的肿瘤抑制功能分类揭示此前研究不足的功能性肿瘤抑制因子及复杂的肿瘤抑制格局。
研究设计与样本
- 采用多重组小鼠模型,在体内评估48个已知和推定肿瘤抑制基因对致癌KRAS驱动肺癌多个致癌环节的影响。
主要发现
- 部分基因失活显著增加肿瘤生长,另一些基因失活增加肿瘤起始和/或异常大肿瘤的出现。
临床怎么用
- 该功能分类有助于理解癌症演化、解读临床癌症基因组测序数据,并指导限制肿瘤起始和进展的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer genotyping has identified a large number of putative tumor suppressor genes. Carcinogenesis is a multistep process, but the importance and specific roles of many of these genes during tumor initiation, growth, and progression remain unknown. Here we use a multiplexed mouse model of oncogenic KRAS-driven lung cancer to quantify the impact of 48 known and putative tumor suppressor genes on diverse aspects of carcinogenesis at an unprecedented scale and resolution. We uncover many previously understudied functional tumor suppressors that constrain cancer in vivo. Inactivation of some genes substantially increased growth, whereas the inactivation of others increases tumor initiation and/or the emergence of exceptionally large tumors. These functional in vivo analyses revealed an unexpectedly complex landscape of tumor suppression that has implications for understanding cancer evolution, interpreting clinical cancer genome sequencing data, and directing approaches to limit tumor initiation and progression. SIGNIFICANCE: Our high-throughput and high-resolution analysis of tumor suppression uncovered novel genetic determinants of oncogenic KRAS-driven lung cancer initiation, overall growth, and exceptional growth. This taxonomy is consistent with changing constraints during the life history of cancer and highlights the value of quantitative in vivo genetic analyses in autochthonous cancer models.This article is highlighted in the In This Issue feature, p. 1601.
引用
- Cai H, Chew SK, Li C, et al. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer. Cancer Discov. 2021. PMID: 33608386. doi:10.1158/2159-8290.CD-20-1325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。